This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...

They’re the seemingly miraculous solution to weight loss, helping people shed stubborn pounds that other diet and food ...

Novo Nordisk has won a Committee for Medicinal Products for Human Use (CHMP) endorsement for a higher-dose version of its diabetes drug liraglutide that can be used to treat obesity. The Danish ...

Dr Ellen Fallows answers key questions on the prescribing of medications for weight loss in patients with obesity ...

Insurers cite unsustainable costs as GLP-1 benefits disappear, accelerating a national shift in employer-sponsored ...

THE number of people taking “fat jabs” such as Mounjaro and Ozempic is on the rise. However, they present serious risks to ...

Trends shaping GLP-1 landscape include FDA regulatory updates, rapid oral drug adoption, and shifting clinical evidence for diabetes care.

As the pharma patent cliff approaches, delve into which important drugs are about to lose exclusivity and how the industry is reacting.

Biocon aims for growth through new biosimilar launches and expanded insulin capacity, projecting significant revenue contributions from key products.

Novo Nordisk’s UK unit has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to what was described as “serious breaches” of the trade ...

Ireland has been chosen as the manufacturing site to make the weight loss drug Wegovy in tablet form. It is currently is only available in this country to use as an injection but its maker, Novo ...